Charles Loprinzi, MD, Mayo Clinic, discusses managing chemotherapy-induced peripheral neuropathy in adult patients with cancer.
Charles Loprinzi, MD, Mayo Clinic, discusses managing chemotherapy-induced peripheral neuropathy in adult patients with cancer.
When patients present with symptoms of chemotherapy-induced neuropathy, healthcare professionals need to weigh the benefits of continuing therapy.
Loprinzi says that he tends to stop treatment early in patients with neuropathy in order to prevent the condition from becoming chronic.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
2 Clarke Drive
Cranbury, NJ 08512